EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen



Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen



Clinical Therapeutics 28(4): 475-490



Background: Ibandronate, a nitrogen-containing bisphosphonate, was approved by the US Food and Drug Administration (FDA) in May 2003 as a daily oral regimen for the treatment and prevention of postmenopausal osteoporosis. In March 2005, the FDA approved once-monthly dosing with ibandronate for the same indications.Objective: The purpose of this article was to review the efficacy and tolerability of ibandronate 150 mg once monthly in the treatment and prevention of postmenopausal osteoporosis.Methods: A search of MEDLINE (1966-September 2005) and International Pharmaceutical Abstracts (1971-September 2005) for articles relating to the efficacy and tolerability of once-monthly ibandronate in the treatment of postmenopausal osteoporosis was conducted using the terms ibandronate and ibandronic acid. Additional searches were conducted to identify publications relevant to compliance and pharmacoeconomic considerations using the terms bisphosphonate, compliance, cost, and pharmacoeconomics. The reference lists of identified articles and presentations from recent scientific meetings also were reviewed. Selected safety information from the manufacturer was incorporated.Results: Ibandronate 2.5 mg/d and intermittent ibandronate (20 mg QOD for 12 doses every 3 months) have been shown to effectively reduce the incidence of vertebral fractures; after 3 years of therapy in a placebo-controlled clinical trial, the relative risk reductions for new vertebral fractures with daily and intermittent ibandronate were 62% and 50%, respectively (both, P < 0.001 vs placebo). Once-monthly ibandronate has been evaluated in 2 clinical trials: a Phase I dose-ranging trial in 144 healthy post-menopausal women and a Phase III noninferiority trial in 1609 women with postmenopausal osteoporosis who were randomized to receive ibandronate 2.5 mg/d or 1 of 3 monthly ibandronate regimens: 50150 mg (50 mg given on 2 consecutive days) once monthly; 100 mg once monthly; and 150 mg once monthly. The primary end point of the Phase III trial was the change from baseline in lumbar spine bone mineral density (BMD). After I year of therapy, patients who received ibandronate 150 mg once monthly had a significantly greater increase from baseline in lumbar spine BMD compared with those who received ibandronate 2.5 mg/d (4.9% vs 3.9%, respectively; P = 0.002). The overall adverse-event profile was similar between the daily and monthly regimens. Drug-related, adverse events were reported in 32.4% of patients receiving ibandronate 2.5 mg/d and 36.9% of patients receiving ibandronate 150 mg monthly. Upper gastrointestinal adverse events occurred in a respective 22.8% and 22.5% of the 2 groups. After I year of therapy, patients receiving ibandronate 150 mg monthly reported more flulike symptoms (8.3%) compared with those receiving ibandronate 2.5 mg/d (2.8%). In a crossover study comparing preference for and convenience of monthly ibandronate and weekly alendronate in 342 ambulatory women with postmenopausal osteoporosis, significantly more patients preferred the monthly ibandronate regimen to the weekly alendronate regimen (71.4% vs 28.5%, respectively; P < 0.001).Conclusion: Once-monthly ibandronate is an effective and well-tolerated treatment option for postmenopausal osteoporosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 012376116

Download citation: RISBibTeXText

PMID: 16750461

DOI: 10.1016/j.clinthera.2006.04.006



Related references

A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcified Tissue International 92(1): 59-67, 2013

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clinical Therapeutics 31(7): 1497-1510, 2009

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean Journal of Internal Medicine 26(3): 340-347, 2012

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. Journal of Bone and Mineral Research 16(10): 1871-1878, 2001

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment. Women's Health 2(3): 341-349, 2006

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2016

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 2(1): 3-18, 2008

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, September, 2001

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. Bone 46(6): 1626-1632, 2010

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Journal of Bone and Mineral Research 20(8): 1315-1322, 2005

The MOTION study: Tolerability of monthly ibandronate and weekly alendronate in women with postmenopausal osteoporosis. 2007

Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile. 2006

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 94(1): 171-180, 2008

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases 65(5): 654-661, 2005